# Mingche

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mingche

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Latest round: Series A (Aug 7, 2026)
- Investors on record: 4

## About

Based in Zhejiang, China, and founded in 2021, Mingche Biotechnology (Suzhou) Co., Ltd., trading as Mingche, is an ophthalmic medical device developer focusing on minimally invasive ophthalmic treatments. In August 2026, Mingche raised a Series A+ funding led by YuanBio Venture.

Its product pipeline comprehensively covers anterior and posterior segment diseases and minimally invasive treatments, forming a multi-dimensional product matrix centered on minimally invasive glaucoma drainage (MIGS) series products and ICL lenses, extending to retinal microneedles and vascular interventional micro-nano robots.

The company’s revenue is generated by selling ophthalmic medical devices and related solutions.

The Series A+ funding raised in August 2026 will be mainly used for two directions: first, to promote the domestic and overseas registration and certification of the minimally invasive glaucoma drainage tube (MIGS), accelerating the internationalization of its product portfolio; and second, to accelerate the research and clinical development of the phakic posterior chamber refractive lens (ICL).

## Funding rounds

- Series A, Aug 7, 2026 — YuanBio Venture
- Series A, Nov 17, 2025 — Oriza Holdings, Zijin Venture Capital, Yunsong Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Zijin Venture Capital (https://capitalatlas.ai/funds/zijin-venture-capital) — Series A
- Yunsong Capital (https://capitalatlas.ai/funds/yunsong-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A